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Introduction: The objective of this study was to quantitate and compare ipsilateral
total N-acetyl aspartate (tNAA), creatine (Cr), choline (Cho), myo-inositol (m-Ins) and
glutamate plus glutamine (Glx) levels in the hippocampi of patients with temporal
lobe epilepsy (TLE) with and without magnetic resonance imaging (MRI) evidence for
mesial temporal sclerosis (MRI positive/negative).
Patients and methods: Twenty-three age matched healthy controls and 26 consecu-
tive patients with unilateral TLE, based on intensive 24 h video-EEG, were investi-
gated with proton magnetic resonance spectroscopy (1H-MRS) (17 with unilateral
hippocampal sclerosis (HS) in MRI–—MRI positive; 9 MRI negative). For statistical
analysis one-way analysis of variance (ANOVA) with post hoc multiple comparisons
and Bonferroni correction was applied. The significance level was based on p < 0.05.
Results: The mean tNAA level ipsilateral to the seizure focus was significantly
decreased in MRI negative, respectively MRI positive patients in comparison to healthy
controls ( p < 0.001). The lowest tNAA level was noticed in the MRI positive group
( p < 0.001). Statistical analysis highlighted a clear ‘‘tNAA cut-off’’ (95% confidence
interval) between MRI positive- and MRI negative patients and healthy controls. Mean
level of Glx and m-Ins was not significantly elevated or reduced. However, in
individual cases a significant elevation was noticed for Glx in MRI negative patients,
respectively for m-Ins in MRI positive patients.* Corresponding author at: Department of Neuroradiology, Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6
Kopfklinik), 91054 Erlangen, Bavaria, Germany. Tel.: +49 9131 85 39388; fax: +49 9131 85 36179.
E-mail addresses: marc.doelken@uk-erlangen.de, marcdoel@gmx.de (M.T. Doelken).
059-1311/$ — see front matter # 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Conclusion: MRI negative TLE patients have a different MRS profile than MRI positive
patients (HS) with marginal but significant decrease of tNAA. Our results reveal a clear
‘‘tNAA cut-off’’ between the groups. The value of m-Ins and Glx in focus detection in
TLE patients remains controversy.
# 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Hippocampal sclerosis (HS) is the most common
finding in patients with temporal lobe epilepsy
(TLE). It can be verified with high reliability (up
to 90% sensitivity and 85% specificity) using mag-
netic resonance imaging (MRI) and is believed to
reflect a combination of initial damage from an
early injury and subsequent seizure-associated
damage.1—4 However, no pathological MRI findings
in TLE patients are reported in up to 30%.5,6 It
remains controversy whether this is due to initial
disease stages which do not display lesional findings
in MRI because of subtle tissue alterations or based
on different illness-entities affecting hippocampal
structures.7 In case of initial disease stage high field
MRI of 3 T or above might be able to detect more
subtle tissue pathology.
The search for metabolite alterations which are
involved in the epileptogenic process is the topic of
recent studies which try to enlighten the underlying
pathology. Proton magnetic resonance spectroscopy
(1H-MRS), which is a non-invasive tool used in clin-
ical settings, plays an increasing role in the detec-
tion of metabolite alterations in the mentioned
patient group.6,8—11 Measurements of total N-acetyl
aspartate (tNAA) have proven to be reliable in
lateralizing the affected hemisphere in patients
with TLE. A decrease of tNAA is accepted as an
objective marker for neuronal loss or dysfunc-
tion.10,12—14 The excitatory amino acid neurotrans-
mitters glutamate and glutamine have been
consistently involved in the pathophysiology of
TLE. 1H-MRS studies reported that glutamate plus
glutamine (Glx) levels are increased ipsilateral,
respectively contralateral15 to the seizure focus in
MRI negative TLE patients.11,14—16 However, a recent
3 T study found no significant differences in Glx
concentrations in TLE patients in comparison to
healthy controls.17 Other 1H-MRS studies of TLE have
focused on myo-inositol (m-Ins) which has been
implicated in intracellular signalling and in osmor-
egulation.18 In mesial TLE reduced and elevated m-
Ins concentrations have been described in the epi-
leptogenic foci.4,19
The objective of this study was to investigate
specific metabolic changes of tNAA, creatine (Cr),
choline (Cho), m-Ins and Glx levels in the hippo-
campi of TLE patients with and without MRI evi-dence for mesial temporal sclerosis (MRI positive
and MRI negative). Different metabolite alterations
were attributed to the mentioned entities in order
to specify and localize the primary epileptogenic
regions. This information is important for under-
standing of underlying pathogenesis and prospec-
tively therapeutic schedules.Patients and methods
Subjects
Twenty-three control subjects (median age 34, 22—
48 years) and 26 consecutive patients diagnosed
with TLE (median age 35, range 19—62 years) were
investigated with 1H-MRS. Diagnosis of unilateral
TLE was based on clinical history, seizure description
and results of intensive video-EEG monitoring. All
patients were very homogenous in clinical features
and suffered from epilepsy with simple partial,
complex partial and secondary tonic—clonic sei-
zures. All patients were classified as unilateral by
interictal/ictal EEG recordings. Nine TLE (median
age 33, range 23—45 years) patients demonstrated
no lesional findings in MRI (MRI negative) as deter-
mined by two independent and experienced neuror-
adiologists. Seventeen TLE patients (median age 36,
range 19—62 years) showed ipsilateral lesional find-
ings (MRI positive) to EEG. MRI imaging gave evi-
dence for HS by hippocampal atrophy and signal
increase in T2 weighted (T2w) images. Patients with
HS in MRI were operated and showed HS in their
specimen which was analyzed in our neuropatholo-
gical institute.
EEG monitoring
The simultaneous registration of continuous video-
EEG monitoring was performed using the Glonner
system (Munich, Germany). Patient behaviour was
recorded via a split-screen technique day and night
over a period of 1—2 weeks. Technical details are:
number of EEG/Polygraphic channels 64/128, sam-
pling rate 200 Hz; storage of video-EEG data on
videotapes and EEG data on the computer for ana-
lysis and reviewing. EEG electrodes were placed
according to the international 10/20 system of
EEG. Additionally, a basal ring of electrodes (S01—
492 M.T. Doelken et al.S02; F11—F12; TP9—TP10, FT9—FT10) and sphenoi-
dal electrodes were placed in order to evaluate
interictal and ictal epileptic activity in temporal
lobes more sufficiently. EEG analysis was performed
using continuous 24 h day and night video-EEG mon-
itoring according to therapeutic intensive seizure
analysis (TISA) described by Stefan et al.20 Epilepti-
form discharges (IEDs) were calculated by the num-
ber of IEDs counted on either side as a percentage of
the total number of IEDs recorded on both sides.
Unilateral interictal and ictal activity were defined
by IEDs which showed 80% of unilateral activity.
EEG analysis was performed blinded to 1H-MRS.
High resolution MR imaging
MR imaging was performed at 1.5 T Siemens Mag-
netom Sonata (Siemens Medical Solutions, Erlangen,
Germany) with a standard head coil and included
the following sequences: T2w, fluid attenuated
inversion recovery (FLAIR), transversal angulated
(parallel to the long axis of the hippocampi; TR
10000, TE 109, slice thickness 5 mm); T2w perpen-
dicular to the long axis of the hippocampi (TR 7420,
TE 98, slice thickness 3 mm); T2*w gradient echo
(FLASH; TR 858, TE 26, slice thickness 5 mm); T1w
3D gradient echo (MP Rage; 1 mm 3D-postproces-
sing, TR 2030, TE 3.93, matrix 256  256); T1w
inversion recovery, perpendicular to the long axis
of the hippocampus (TR 9650, TE 16, slice thickness
3 mm); T1w Gadolinium enhanced at first admit-
tance to exclude other pathologic alterations (e.g.
inflammatory disease, cavernoma). Patients with
evidence for extra-hippocampal pathology were
excluded. The criteria for a diagnosis of HS on MRFigure 1 The MR image illustrates hippocampal voxel of inte
3 mm).images included the presence of unilateral atrophy
and high T2w signal of the hippocampus.
Single voxel spectroscopy (SVS)
At the time of scanning, patients in both groups were
seizure free for at least 3 days. All experiments were
carried out using a 1.5 T Siemens Magnetom Sonata
(Siemensmedical solutions, Erlangen,Germany) clin-
ical whole body MR scanner using a standard head
coil. To obtain optimal signal demarcation of the
hippocampus from the amygdala and avoid cere-
brospinal fluid (CSF) contamination of the ventricular
system sagittal, transversal and coronar T2w images
in three orthogonal planes were used as localizer
(Fig. 1). The voxel comprised the head and anterior
body portion of the hippocampus. In order to mini-
mize partial-volume effects, the voxel size was
reduced to a minimum of 2 cc arising from an edge
length of 20 mm in the sagittal axis and 10 mm in the
coronal and transversal axis. In the healthy control
group and in patients with no pathological findings in
MRI there was no hippocampal atrophy and the voxel
comprised mainly hippocampal tissue. The partial-
volume effect in these groups was determined by
segmenting on coronal T2w images and was less than
10% of the voxel. In patients with hippocampal atro-
phy due to HS CSF fraction (partial-volume effect) in
the hippocampal voxel was determined by segment-
ing on coronal T2w images as well. The corrections of
each metabolite for CSF dilution was carried out by
the formula: Ccorr = (Cmeas  100)/(100  CSFperc.)–—
Cmeas refers tomeasuredconcentrationofmetabolite
of the whole voxel, CSFperc. is the percentage of CSF
in the voxel.rest (VOI) of 1H-MRS (T2w, TR 7420, TE 98, slice thickness
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prior to the ‘‘point resolved spectroscopy’’ (PRESS)
were implemented for water suppression; repeti-
tion time (TR) 3000 ms; echotime (TE) 30 ms;
averages 128; vector size 1024. Determination of
the absolute metabolite concentrations in SVS was
carried out by water scaling, a method in which the
resonance area of the unsuppressed water signal is
used as an internal reference. An appropriate
water-unsuppressed voxel of identical voxel loca-
lization and measurement parameters was
obtained for each water-suppressed voxel, differ-
ing only in the number of acquisitions that were
reduced to 12. tNAA, Cho, Cr, Glx and m-Ins were
quantified using LCModel,21 which is a user-inde-
pendent time domain spectral fitting program.
Water scaling and fitting were carried out automa-
tically. Spectra were not corrected for T1 satura-
tion. All concentrations are estimated metabolite
levels with an unknown degree of T1 saturation and
are referred to as institutional units (arbitrary units
of our institute). Estimated uncertainties by Cra-
mer-Rao lower bounds (CRLB) served as main guide-
lines for judging the spectra of absolute metabolite
concentrations. Only metabolite spectra with
LCModel estimated uncertainty of <15% standard
deviation (S.D.) of the evaluated concentrations
and spectrawith an SNR (signal to noise ratio) above
3 were included in this study. Spectra with a
FWHM > 0.065 ppm were not included in the study.
For further details see Hammen et al.22 and Pro-
vencher and Helms et al.21,23,24 Analysis of meta-
bolite spectra was performed blinded to EEG and
MRI results.Table 1 Mean metabolite level ipsilateral to EEG focus in M




Groups N Mean Stand
devia
(S.D.
tNAA MRI pos. 17 4.59 0.68
MRI neg. 9 5.82 0.78
controls 21 6.91 0.55
Glx MRI pos. 17 9.74 2.09
MRI neg. 9 11.10 2.33
controls 21 9.45 1.56
m-Ins MRI pos. 17 5.78 1.36
MRI neg. 9 5.47 1.31
Controls 21 4.98 0.86
Statistical evaluation demonstrated significant tNAA reduction in M
controls (*p < 0.001). Additionally, tNAA level of MRI positive patien
(#p < 0.001). Increase of Glx level in MRI negative- and m-Ins level in
reach statistical significance ( p > 0.05). No statistical significance i
(results not included in Table 1). One-way analysis of variance (AN
patients; N, patient numbers; ns, not statistically significant ( p > 0
negative patients.Statistics
Statistical analysis was carried out by SPSS 15.
Normal distributions of metabolite concentrations
were verified by the Kolmogorov—Smirnov test.
Metabolite values were classified as pathological
if the deviation from the mean of the healthy con-
trols exceeded 2 S.D.s. Descriptive statistics (mean
(M), S.D. and 95% confidence interval (95% CI)) were
calculated. For statistical analysis one-way analysis
of variance (ANOVA) with post hoc multiple compar-
isons and Bonferroni correction was applied. The
statistical significance level was based on p < 0.05.Results
The mean level of tNAA ipsilateral to seizure focus
was significantly decreased in MRI positive-
(4.59  0.68) and MRI negative (5.82  0.78)
patients in comparison to healthy controls
(6.91  0.55) (ANOVA F = 60.2, d.f. = 2/46,
p < 0.001, Table 1). Additionally, tNAA level of
MRI positive patients was significantly reduced com-
pared to MRI negative patients (post hoc test (Bon-
ferroni) p < 0.001, Fig. 2). Fig. 3 delineates the
strictly separated tNAA 95% confidence intervals
of the different groups, highlighting the clear ‘‘tNAA
cut-off’’ between MRI positive- and MRI negative
patients and healthy controls (95% confidence inter-
vals: MRI positive 4.25—4.95; MRI negative 5.22—
6.34; healthy controls 6.67—7.12). The highest tNAA
reduction compared to healthy controls was seen in








comparisons ( p = 0.01)
4.25 4.95 <0.001 * <0.001#
5.22 6.43 <0.001 *
6.67 7.12
8.47 11.00 ns *
9.31 12.89 ns *
8.74 10.16
5.05 6.50 ns *
4.38 6.57 ns *
4.59 5.37
RI positive- and MRI negative patients in comparison to healthy
ts was significantly reduced compared to MRI negative patients
MRI positive patients in comparison to healthy controls did not
n group comparison of mean ipsilateral Cho and Cr was noticed
OVA); MRI pos., MRI positive patients; MRI neg., MRI negative
.05); *in comparison to healthy controls; #MRI positive vs. MRI
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Figure 2 Group comparison of tNAA levels ipsilateral to
EEG focus (box plot). The lowest tNAA levels were noticed
in the MRI positive group. Nevertheless, MRI negative
patients also displayed significantly reduced tNAA levels
( p < 0.05) in comparison to healthy controls (Y-axis = in-
stitutional units).
Figure 4 Group comparison of Glx levels ipsilateral to
EEG focus (box plot). In the MRI negative group mean Glx
level was not significantly elevated ( p > 0.05), however,
in individual cases a significant elevation was noticed.cant reduction of tNAA was noticed in the MRI
negative group.
All MRI positive patients showed ipsilateral tNAA
reduction exceeding 2 S.D. compared to healthy
controls. Six out of nine MRI negative patients
demonstrated a reduction of more than 2 S.D. of
tNAA.
Mean Glx level ipsilateral to seizure focus in MRI
negative patients (11.10  2.33) was increased com-
pared to the MRI positive patients (9.74  2.09) and
healthy controls (9.45  1.56) (Fig. 4). However, only
two out of nine MRI negative patients showed a
significant elevation of more than 2 S.D. of Glx.
Results did not reach statistical significance usingFigure 3 This graphic delineates that alterations in
spectral tNAA can distinctively be assigned to the differ-
ent groups (95% confidence interval–—MRI positive, MRI
negative and healthy controls). Our results demonstrate a
clear ‘‘tNAA cut-off’’ between the three groups.ANOVA with Bonferroni corrected post hoc multiple
comparisons.
Mean m-Ins level ipsilateral to seizure focus was
increased in MRI positive patients (5.78  1.36)
compared to MRI negative patients (5.47  1.31)
and healthy controls (4.98  0.86) (Fig. 5). How-
ever, only 4 out of 17 MRI positive patients showed a
significant elevation of more than 2 S.D. of m-Ins.
Results did not reach statistical significance using
ANOVA.
No statistical significance in-group comparison of
mean ipsilateral Cho and Cr was noticed.
Contralateral tNAA reduction was found in 22%
(2/9) in the MRI negative group versus 18% (3/17) in
MRI positive patients. Other contralateral metabo-
lites were within the normal range, apart from
increased Glx level in one MRI negative patient.Figure 5 Group comparison of m-Ins levels ipsilateral to
EEG focus (box plot). In the MRI positive group mean m-Ins
level was not significantly elevated ( p > 0.05), however
in individual cases a significant elevation was noticed.
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Total NAA level has the lowest variation coefficient
of all detectable brain metabolites.22 It is decreased
ipsilateral to lesion, respectively EEG focus in TLE
patients with evidence for HS,1,2,11,17,25 which is
either due to neural cell loss or neuronal dysfunc-
tion.6,8,10,12—14,26 In patients with HS reduction of
tNAA can partially be explained with neural loss as it
is believed to be located primarily within neu-
rons.11,27,28 The question how epileptic discharges
in TLE patients with normal findings in MRI are
related to marginal neuronal loss or metabolic dys-
function still remains unclear.
To our knowledge this is the first study that high-
lights a clear ‘‘tNAA cut-off’’ between MRI positive-
and MRI negative patients and healthy controls.
However, Woermann et al.11 reported that the
decrease of NAA was less marked in MRI negative
hippocampi on the side of seizure onset than in HS.
Fig. 3 delineates that alterations in spectral tNAA
can distinctively be assigned to the different groups
(95% confidence interval). Despite the limited
patient numbers the distinct ‘‘tNAA cut-off’’
between the groups is remarkable. The highest
degree of tNAA reduction compared to healthy con-
trols was seen in the MRI positive group (Figs. 2 and
3). A moderate but still significant reduction of tNAA
was noticed in the MRI negative group. The minor
degree of tNAA reduction in the MRI negative group
may be attributed to a minor lesion of unknown
underlying cause, respectively initial disease stage.
This leads to functional deficit and not to lesional
findings detectable by imaging modalities as MRI.7 In
further progress disease alterations become more
pronounced, visible in MRI as lesions and easier to
detect in 1H-MRS and multimodal imaging (e.g.
single photon emission computed tomography
(SPECT) and positron emission tomography
(PET)).9,29 In this case high field MRI of 3 T or above
and different contrast type might be able to detect
more subtle tissue pathology.
Several studies have addressed the role of spec-
tral metabolite markers using histopathological cor-
relations.30,31 The correlation between spectral
metabolite alterations (tNAA) and the degree of
neuronal loss was confirmed by Duc et al.1 In vitro
1H-MRS of hippocampal specimen at 11.75 T did not
reveal a significant association between hippocam-
pal neuron loss and cellular content of tNAA.13
Therefore, the reduction of tNAA was attributed
to neuronal dysfunction caused by compromised
mitochondrial pathways.
Glx consists of glutamine and glutamate which
are present in both neuronal and in glial cells. With
1.5 T scanners separation of glutamine and gluta-mate peaks is not possible, thus the mechanisms
underlying the elevated Glx level in individual cases
of MRI negative patients in our study and in other
studies11 must be speculative. In our study mean Glx
level in the MRI negative group was not significantly
elevated after Bonferroni corrected post hoc multi-
ple comparisons. High intracellular glutamate con-
centrations or elevated release of glutamate could
contribute to increased electrical irritability,
respectively promoting excitotoxicity.11,14,32,33
Owing to conversion of glutamate to glutamine in
astrocytes, energy failure due to hampered mito-
chondrial respiration und ATP synthesis might lead
to accumulation of intracellular glutamate. Addi-
tionally, possible high levels of extracellular Glx
arise. Further studies are needed to evaluate this
issue, particularly because there has been some
discrepancy concerning elevated Glx levels in TLE
patients.4,11,14,15,17,25
Alike to Glx the role of m-Ins remains controversy.
Wellard et al.4 reported elevated m-Ins in the epi-
leptogenic temporal lobe of patients with HS. He
concluded that m-Ins changes may distinguish
between the seizure focus, where m-Ins is increased
and areas of seizure spread like in the frontal lobe
where m-Ins is decreased. This might help to dis-
tinguish drug refractory TLE patients, who will ben-
efit from surgery by excluding bilateral foci which is
of importance for predicting postoperative out-
come.9,12,34—36 Contrary to these results, Riederer
et al.17 and Mueller et al.19 reported lower m-Ins
levels in patients with mesial TLE. In our study mean
m-Ins level was not significantly elevated or reduced
after Bonferroni corrected post hoc multiple com-
parisons, however in individual cases a significant
elevation was noticed in the MRI positive group.
Cerebral m-Ins concentrations are possibly affected
through seizures and antiepileptic drug treatment
which might explain contradictory results.17,37,38
Therefore, as concluded by Riederer et al.17 the
relation between epilepsy and m-Ins has to be
investigated in other models.Conclusion
MRI negative TLE patients have a different MRS
profile than MRI positive patients (HS) with marginal
but significant decrease of tNAA. Our results high-
light a clear ‘‘tNAA cut-off’’ (95% confidence inter-
val) between the groups. The minor degree of tNAA
reduction in the MRI negative group may be attrib-
uted to minor lesions of unknown underlying cause.
This leads to functional deficit and not to lesional
findings. Higher field MRI of 3 T or above might be
able to detect more subtle tissue pathology. The
496 M.T. Doelken et al.value of m-Ins and especially Glx in MRI negative TLE
patients remains controversy. Adequate statistical
analysis and larger patient numbers are necessary as
demonstrated in this study.References
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